ArticleJournal of translational medicine2026
ARF-like GTPase 8B orchestrates lipophagy and exocytosis to drive single-stranded RNA virus replication.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSingle-stranded RNA (ssRNA) viruses, including foot‑and‑mouth disease virus (FMDV), enterovirus 71 (EV71), and vesicular stomatitis virus (VSV), reprogram host lipid metabolism to facilitate replication. However, the mechanisms governing virus‑induced lipid droplet (LD) degradation remain poorly defined, which limits the development of host‑directed antiviral strategies.
methodsWe employed virological, biochemical, and imaging approaches to investigate the role of the lysosomal GTPase ARL8B in ssRNA virus infection. Lipid droplet dynamics, lipophagy, and lysosomal exocytosis were assessed using confocal microscopy and biochemical assays. Small‑molecule inhibitors targeting ARL8B were identified through virtual screening and validated in vitro for antiviral activity. The in vivo efficacy of selected inhibitors was evaluated in a murine EV71 infection model, with disease severity and survival as endpoints.
resultsARL8B was identified as a central host factor that promotes replication of multiple ssRNA viruses by coordinating LD degradation with viral egress. Mechanistically, ARL8B drove lysosome‑dependent LD breakdown via selective lipophagy, releasing free fatty acids that fuel membrane remodeling within viral replication complexes. Concurrently, ARL8B facilitated viral exit through a noncanonical lysosomal-exosome pathway, enhancing progeny virus dissemination. Virtual screening yielded small‑molecule ARL8B inhibitors that potently suppressed ssRNA virus replication in vitro. In a murine EV71 infection model, these inhibitors provided robust protection and substantially reduced disease severity.
conclusionsOur findings establish ARL8B as a key host factor coupling lipid catabolism with viral export, and unveil a class of broad‑spectrum antiviral candidates targeting a lipid reprogramming node essential for multiple pathogenic RNA viruses. This study provides a mechanistic framework for developing host‑directed antiviral therapies against ssRNA viruses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.